TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02050802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Study: NCT02338804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV
Description: MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study: NCT01134783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHOICES Intervention
Description: Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
Study: NCT04316715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifesteps for PrEP
Description: Four weekly nurse delivered counseling sessions plus two optional booster sessions. Sessions last approximately 40-50 minutes each. Sessions employ cognitive behavioral (CBT) techniques, motivational interviewing (MI), and psychoeducation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily text message reminders
Description: Participants get daily text messages on their cell phone reminding them to take their PrEP medication.
Study: NCT01080352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (Vitamin C)
Description: 60grams of ascorbate given intravenous infusion in 1000ml sterile water.
Study: NCT01438424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 1.0 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Oral, 100 mg, daily
Study: NCT02239978

Intervention type: BEHAVIORAL
Intervention: Postural perturbation
Description: Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.

Intervention type: BEHAVIORAL
Intervention: Postural perturbation
Description: Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
Study: NCT04508244

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
Study: NCT02152696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Evacuation
Description: Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectant Management
Description: Pregnancy will be expectantly managed using serum hcg monitoring
Study: NCT04010708

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Iodine Concentration Measurement
Description: UIC
Study: NCT04624568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAPILOCARE
Description: Papilocare® is a self-administered vaginal gel. Its single-dose cannula contains hyaluronic acid and pre-biotics (Coriolus Versicolor) that would improve the re-epithelialization of the uterin cervix. By creating a protective film on the cervix, this gel could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus.~The specific approach related to our study would be to apply Papilocare® vaginal gel for 6 months for the treated group.~Smear and HPV test will be perform by all patients at 6 and 12 months.
Study: NCT00763477

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ghrelin
Description: subcutaneous injection
Study: NCT04351321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally Laparoscopic Total Gastrectomy
Description: Totally laparoscopic total gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy-Assisted Total Gastrectomy
Description: Laparoscopy-Assisted Total Gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
Study: NCT05689957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block using intravenous rocuronium induction at 1.2mg/kg and maintainance of 8-12mcg/kg/min for deep neuromuscular block
Description: both arm are using low pressure pneumoperitoneum in laparoscopic surgery, moderate and deep neuromuscular block are monitor with neuromuscular monitoring. if surgical condition is inadequate, surgeon are allowed to increase intraabdominal pressure as per standard care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deep neuromuscular block using intravenous rocuronium induction at 1.2mg/kg and maintainance of 8-12mcg/kg/min for deep neuromuscular block
Description: both arm are using low pressure pneumoperitoneum in laparoscopic surgery, moderate and deep neuromuscular block are monitor with neuromuscular monitoring. if surgical condition is inadequate, surgeon are allowed to increase intraabdominal pressure as per standard care
Study: NCT01675466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early laparoscopy
Description: Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic instruments
Study: NCT03238612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFA, clarithromycin, oseltamivir
Description: 2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir alone
Description: 2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
Study: NCT03231566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: See arm/group description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Neuroscience Education
Description: See arm/group description
Study: NCT02566434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: methionine
Description: 4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
Study: NCT02501473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G100
Description: GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G100
Description: GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G100
Description: GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G100
Description: GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G100
Description: GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
Study: NCT03090711

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Transcranial Magnetic Stimulation (TMS)
Description: Sham coil will be used to exclude possible nonspecific effects of the TMS. The sham coil is shielded i.e., the magnetic field output is weakened and therefore insufficiently powerful to stimulate the cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Transcranial Alternating Current Stimulation (tACS)
Description: Sham stimulation will be used to exclude possible nonspecific effects of the tACS. Sham tACS stimulation will involve actual stimulation for the first 30 seconds of the ramp-up period (stimulation power is gradually increased until its final level), and then immediately gradually decreased until zero (without the intermediate 4 minutes of actual stimulation). This procedure will be repeated 5 times every 6 minutes and shall induce similar cutaneous sensations as real stimulation.
Study: NCT02050802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02987361

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC-STIMULATOR PLUS
Description: 2mA for 20minutes a day, 5 days per weeks, totally 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-STIMULATOR PLUS
Description: 2mA for 20minutes a day, 5 days per weeks, totally 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-STIMULATOR PLUS
Description: 2mA for 20minutes a day, 5 days per weeks, totally 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-STIMULATOR PLUS
Description: 2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
Study: NCT02645643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education of medical humanities
Description: The medical students in the intervention group would gain education about the medical humanities, but not the control group.
Study: NCT00742989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLT maneuver
Description: direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham OLT
Description: Therapeutic massage performed
Study: NCT01858545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MatriStem
Description: MatriStem MicroMatrix and MatriStem Wound Matrix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellular Dermal Replacement Tissue
Description: Cellular Dermal Replacement Tissue
Study: NCT03549208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBVE01
Description: Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBVE02
Description: Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: 13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
Study: NCT03854526

Intervention type: OTHER
Intervention: Evaluation of the quality of direct and indirect partial dental coronal restorations in adults
Description: The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning.

Intervention type: OTHER
Intervention: Evaluation of the quality of direct and indirect partial dental coronal restorations in adults
Description: The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning.
Study: NCT02734771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT02803177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMC2012

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: beta-TCP Chronos® Synthes
Study: NCT00885586

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-laser acupuncture
Description: Laser irradiation is faked, approaching a non-functioning laser pen.
Study: NCT02501473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G100
Description: GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G100
Description: GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G100
Description: GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (anti-CD20 antibody)
Study: NCT04369521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low free sugar diet
Description: low free sugar diet with nutrition and exercise recommendation
Study: NCT03157778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obese men
Description: Biological measures before, just before, and after lunch, in obese men

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal-weight men
Description: Biological measures before, just before, and after lunch, in normal-weight men.
Study: NCT03630172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Using a thin, filiform needle to penetrate a muscle and its trigger point to produce a local twitch response

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needling
Description: Using a thin, filiform needle to penetrate a muscle and its trigger point to produce a local twitch response
Study: NCT06040372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB64640
Description: The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is provided as a matching placebo
Study: NCT02524795

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hiomega-3 supplement of Naturalis® company -
Description: Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
Study: NCT02597075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy + physical activity program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Study: NCT04287244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Direct Current Stimulation
Description: tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Spinal Direct Current Stimulation
Description: tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
Study: NCT02156596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV NSAI
Description: 100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM
Description: 3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Serum Saline
Description: 50 ml of SS is given by IV root over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised Serum Saline
Description: 3 nebulisations of 5ml SS each are given over 30 minutes
Study: NCT00885586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentine
Description: Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer